Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

    Results: 1 to 20 of 31

    1.

    Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial.

    Rosell R, Carcereny E, Gervais R, Vergnenegre A, Massuti B, Felip E, Palmero R, Garcia-Gomez R, Pallares C, Sanchez JM, Porta R, Cobo M, Garrido P, Longo F, Moran T, Insa A, De Marinis F, Corre R, Bover I, Illiano A, Dansin E, de Castro J, Milella M, Reguart N, Altavilla G, Jimenez U, Provencio M, Moreno MA, Terrasa J, Muñoz-Langa J, Valdivia J, Isla D, Domine M, Molinier O, Mazieres J, Baize N, Garcia-Campelo R, Robinet G, Rodriguez-Abreu D, Lopez-Vivanco G, Gebbia V, Ferrera-Delgado L, Bombaron P, Bernabe R, Bearz A, Artal A, Cortesi E, Rolfo C, Sanchez-Ronco M, Drozdowskyj A, Queralt C, de Aguirre I, Ramirez JL, Sanchez JJ, Molina MA, Taron M, Paz-Ares L; Spanish Lung Cancer Group in collaboration with Groupe Français de Pneumo-Cancérologie and Associazione Italiana Oncologia Toracica.

    Lancet Oncol. 2012 Mar;13(3):239-46. Epub 2012 Jan 26.

    PMID:
    22285168
    [PubMed - indexed for MEDLINE]
    2.

    Efficacy and safety of erlotinib versus chemotherapy in second-line treatment of patients with advanced, non-small-cell lung cancer with poor prognosis (TITAN): a randomised multicentre, open-label, phase 3 study.

    Ciuleanu T, Stelmakh L, Cicenas S, Miliauskas S, Grigorescu AC, Hillenbach C, Johannsdottir HK, Klughammer B, Gonzalez EE.

    Lancet Oncol. 2012 Mar;13(3):300-8. Epub 2012 Jan 24.

    PMID:
    22277837
    [PubMed - indexed for MEDLINE]
    3.

    EGFR expression as a predictor of survival for first-line chemotherapy plus cetuximab in patients with advanced non-small-cell lung cancer: analysis of data from the phase 3 FLEX study.

    Pirker R, Pereira JR, von Pawel J, Krzakowski M, Ramlau R, Park K, de Marinis F, Eberhardt WE, Paz-Ares L, Störkel S, Schumacher KM, von Heydebreck A, Celik I, O'Byrne KJ.

    Lancet Oncol. 2012 Jan;13(1):33-42. Epub 2011 Nov 4.

    PMID:
    22056021
    [PubMed - indexed for MEDLINE]
    4.

    Pitfalls in the assessment of prognostic factors.

    Metze K.

    Lancet Oncol. 2011 Nov;12(12):1095-6. No abstract available.

    PMID:
    22041541
    [PubMed - indexed for MEDLINE]
    5.

    Pharmacokinetics of gefitinib and erlotinib.

    Levêque D.

    Lancet Oncol. 2011 Nov;12(12):1093. No abstract available.

    PMID:
    22041538
    [PubMed - indexed for MEDLINE]
    6.

    Therapeutic vaccination with TG4010 and first-line chemotherapy in advanced non-small-cell lung cancer: a controlled phase 2B trial.

    Quoix E, Ramlau R, Westeel V, Papai Z, Madroszyk A, Riviere A, Koralewski P, Breton JL, Stoelben E, Braun D, Debieuvre D, Lena H, Buyse M, Chenard MP, Acres B, Lacoste G, Bastien B, Tavernaro A, Bizouarne N, Bonnefoy JY, Limacher JM.

    Lancet Oncol. 2011 Nov;12(12):1125-33. Epub 2011 Oct 21.

    PMID:
    22019520
    [PubMed - indexed for MEDLINE]
    7.

    Hope without hype: EML4-ALK inhibition for treatment of lung cancer.

    Govindan R.

    Lancet Oncol. 2011 Oct;12(11):983-4. Epub 2011 Sep 18. No abstract available.

    PMID:
    21933750
    [PubMed - indexed for MEDLINE]
    8.

    Effect of crizotinib on overall survival in patients with advanced non-small-cell lung cancer harbouring ALK gene rearrangement: a retrospective analysis.

    Shaw AT, Yeap BY, Solomon BJ, Riely GJ, Gainor J, Engelman JA, Shapiro GI, Costa DB, Ou SH, Butaney M, Salgia R, Maki RG, Varella-Garcia M, Doebele RC, Bang YJ, Kulig K, Selaru P, Tang Y, Wilner KD, Kwak EL, Clark JW, Iafrate AJ, Camidge DR.

    Lancet Oncol. 2011 Oct;12(11):1004-12. Epub 2011 Sep 18.

    PMID:
    21933749
    [PubMed - indexed for MEDLINE]
    Free PMC Article
    9.

    NICE guidance on erlotinib for the maintenance treatment of non-small-cell lung cancer.

    Rinaldi F, George E, Clark P.

    Lancet Oncol. 2011 Aug;12(8):728-30. No abstract available.

    PMID:
    21928488
    [PubMed - indexed for MEDLINE]
    10.

    Are all KRAS mutations created equal?

    Stinchcombe TE, Der CJ.

    Lancet Oncol. 2011 Aug;12(8):717-8. Epub 2011 Jul 22. No abstract available.

    PMID:
    21782508
    [PubMed - indexed for MEDLINE]
    11.

    Erlotinib, gefitinib, or chemotherapy for EGFR mutation-positive lung cancer?

    Mitsudomi T.

    Lancet Oncol. 2011 Aug;12(8):710-1. Epub 2011 Jul 23. No abstract available.

    PMID:
    21783418
    [PubMed - indexed for MEDLINE]
    12.

    Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study.

    Zhou C, Wu YL, Chen G, Feng J, Liu XQ, Wang C, Zhang S, Wang J, Zhou S, Ren S, Lu S, Zhang L, Hu C, Hu C, Luo Y, Chen L, Ye M, Huang J, Zhi X, Zhang Y, Xiu Q, Ma J, Zhang L, You C.

    Lancet Oncol. 2011 Aug;12(8):735-42. Epub 2011 Jul 23.

    PMID:
    21783417
    [PubMed - indexed for MEDLINE]
    13.

    Molecular biomarkers in non-small-cell lung cancer: a retrospective analysis of data from the phase 3 FLEX study.

    O'Byrne KJ, Gatzemeier U, Bondarenko I, Barrios C, Eschbach C, Martens UM, Hotko Y, Kortsik C, Paz-Ares L, Pereira JR, von Pawel J, Ramlau R, Roh JK, Yu CT, Stroh C, Celik I, Schueler A, Pirker R.

    Lancet Oncol. 2011 Aug;12(8):795-805. Epub 2011 Jul 22.

    PMID:
    21782507
    [PubMed - indexed for MEDLINE]
    14.

    EGFR exon 20 insertion mutations in non-small-cell lung cancer: preclinical data and clinical implications.

    Yasuda H, Kobayashi S, Costa DB.

    Lancet Oncol. 2012 Jan;13(1):e23-31. Epub 2011 Jul 19. Review. Erratum in: Lancet Oncol. 2011 Dec;12(13):1182.

    PMID:
    21764376
    [PubMed - indexed for MEDLINE]
    15.

    Genetics of lung cancer susceptibility and COPD.

    Young R, Hopkins R, Etzel C, El-Zein R.

    Lancet Oncol. 2011 Jul;12(7):622-3. No abstract available.

    PMID:
    21708349
    [PubMed - indexed for MEDLINE]
    16.

    Tuberculosis and cancer: a complex and dangerous liaison.

    Vento S, Lanzafame M.

    Lancet Oncol. 2011 Jun;12(6):520-2. No abstract available.

    PMID:
    21624773
    [PubMed - indexed for MEDLINE]
    17.

    Cancer mortality in Northern Ireland.

    Burki T.

    Lancet Oncol. 2011 May;12(5):428. No abstract available.

    PMID:
    21688411
    [PubMed - indexed for MEDLINE]
    18.

    Explaining trends in lung cancer deaths in women.

    Senior K.

    Lancet Oncol. 2011 Mar;12(3):220. No abstract available.

    PMID:
    21495247
    [PubMed - indexed for MEDLINE]
    19.

    New driver mutations in non-small-cell lung cancer.

    Pao W, Girard N.

    Lancet Oncol. 2011 Feb;12(2):175-80. Review.

    PMID:
    21277552
    [PubMed - indexed for MEDLINE]
    20.

    China wrestles with lung cancer.

    Wen C, Dehnel T.

    Lancet Oncol. 2011 Jan;12(1):15. No abstract available.

    PMID:
    21249722
    [PubMed - indexed for MEDLINE]

      Display Settings:

      Format
      Items per page
      Sort by

      Send to:

      Choose Destination

      Supplemental Content

      Find related data

      Recent activity

      Your browsing activity is empty.

      Activity recording is turned off.

      Turn recording back on

      See more...
      Write to the Help Desk